• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH awards $64M for the understanding of cell pathways, development of new therapies

NIH awards $64M for the understanding of cell pathways, development of new therapies

September 16, 2014
CenterWatch Staff

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

The funding establishes six centers, collectively called the Data and Signature Generating Centers. The National Human Genome Research Institute (NHGRI) and the National Heart, Lung, and Blood Institute (NHLBI), both part of NIH, administer the program on behalf of the NIH Common Fund.

The LINCS program aims to catalog and analyze cellular function and molecular activity in response to perturbing agents—such as drugs and genetic factors—that are potentially disruptive to cells. LINCS researchers then will measure the cells’ tiniest molecular and biochemical responses, and use computer analyses to uncover common patterns in these responses—called “signatures.” LINCS data will be freely available to any scientist.

“The simplest way to think about signatures is essentially as broad common patterns, as well as uncommon behavior, in how cells respond to being exposed to various small molecules, genetic perturbations or genetic changes,” said Ajay Pillai, Ph.D., program director in NHGRI’s division of genome sciences. Pillai is co-coordinator of the LINCS program, along with Albert Lee, Ph.D., a program director in NHLBI’s division of cardiovascular sciences. “For example, you could figure out patterns of toxicity of potential new drug compounds by looking at cellular responses and finding common responses to other known toxic molecules.”

A major challenge that will be addressed in the second phase of LINCS is to optimize the combinations of cell types, perturbations and measurements of cellular responses to address a wider range of basic biological and disease-related problems than was possible in the program’s initial pilot stage, said Alan Michelson, M.D., Ph.D., senior investigator, Laboratory of Developmental Systems Biology, NHLBI, and co-chair of the NIH LINCS project implementation team.

Even in its prototype phase, LINCS has produced meaningful results that will aid in improving human health. For example, a research team last year used LINCS data to identify the role of a critical transcription regulator, heat shock factor 1 (HSF1), in cancer. Another team reported that the LINCS approach of measuring a wide range of cells’ responses to drugs was more accurate than conventional drug-potency tests. This recognition may point the way toward more effective therapeutics with fewer unexpected side effects.

Recipients of the new LINCS grants (pending available funds) are:

  • Peter Sorger, Ph.D., at Harvard Medical School, Boston, Mass. This team will receive $12.87 million over six years for development of new measurement methods and computer algorithms to detect and analyze perturbations induced by therapeutic drugs in healthy and diseased human cells.
  • Joe Gray, Ph.D., from Oregon Health and Science University (OHSU), for $10.29 million over six years to study how both malignant and non-malignant cells are controlled by the microenvironments in which they live. 
  • Todd Golub, M.D., from the Broad Institute of the Massachusetts Institute of Technology and Harvard University. He will receive $12.56 million over six years to create a genome-scale catalog of the consequences of cellular perturbation. 
  • Srinivas (Ravi) Iyengar, Ph.D., of Icahn School of Medicine at Mount Sinai, based in New York City. The team recieves $11.39 million over six years to develop cell signatures that will predict adverse events that might be caused by drugs and will identify other drugs that might lessen these side effects. 
  • Jacob D. Jaffe, Ph.D., from the Broad Institute of the Massachusetts Institute of Technology and Harvard University. The $8.9 million over six years will be for seeking patterns from known causes of cell disruption, such as drugs, that can help identify the cause of other instances of cell damage. 
  • Leslie M. Thompson, Ph.D., of the University of California, Irvine. The grant of $8 million over six years is for identifing targets for developing drugs against neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), spinal muscular atrophy and Huntington’s disease. 

Total funding for the LINCS program is set at $64 million over six years. The NIH Common Fund is funding five of the new LINCS grants as part of its Big Data to Knowledge initiative. The National Institute of Neurological Disorders and Stroke (NINDS) is funding Thompson’s grant.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing